MS drug shows promise in long-term safety extension trial

NCT ID NCT03996291

Completed Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 34 times

Summary

This study looked at the long-term safety and effectiveness of the drug SAR442168 in 125 people with relapsing multiple sclerosis who had already completed a previous study. Participants continued taking the drug for up to 240 weeks. The main goal was to track side effects, and the study also measured brain lesions using MRI scans to see if the drug helped control disease activity.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Consultants In Neurology Site Number : 8400001

Northbrook, Illinois, 60062, United States
Investigational Site Number : 1240001

Greenfield Park, Quebec, J4V 2J2, Canada
Investigational Site Number : 1240003

Vancouver, British Columbia, V6T 2B5, Canada
Investigational Site Number : 2030001

Prague, 12808, Czechia
Investigational Site Number : 2030002

Praha 5 - Motol, 15006, Czechia
Investigational Site Number : 2030003

Jihlava, 58633, Czechia
Investigational Site Number : 2030004

Hradec Králové, 50005, Czechia
Investigational Site Number : 2030005

Ostrava - Poruba, 70852, Czechia
Investigational Site Number : 2030006

Pardubice, 53203, Czechia
Investigational Site Number : 2030007

Brno, 62500, Czechia
Investigational Site Number : 2330001

Tallinn, 11315, Estonia
Investigational Site Number : 2500004

Nancy, 54035, France
Investigational Site Number : 5280001

Amsterdam, 1081 HV, Netherlands
Investigational Site Number : 6430001

Saint Petersburg, 197110, Russia
Investigational Site Number : 6430003

Moscow, 125367, Russia
Investigational Site Number : 6430005

Saint Petersburg, 194044, Russia
Investigational Site Number : 6430006

Kazan', 420032, Russia
Investigational Site Number : 6430007

Tyumen, 625000, Russia
Investigational Site Number : 7240001

Madrid, 28007, Spain
Investigational Site Number : 7240002

Barcelona, Barcelona [Barcelona], 08035, Spain
Investigational Site Number : 7240003

Seville, Andalusia, 41009, Spain
Investigational Site Number : 7240004

Murcia, 30120, Spain
Investigational Site Number : 7240005

Salt, Girona [Gerona], 17190, Spain
Investigational Site Number : 8040001

Lviv, 79010, Ukraine
Investigational Site Number : 8040002

Chernivtsi, 58000, Ukraine
Investigational Site Number : 8040003

Vinnytsia, 21005, Ukraine
Investigational Site Number : 8040005

Dnipro, 49038, Ukraine
Investigational Site Number : 8040006

Lviv, 79013, Ukraine
Investigational Site Number : 8040007

Zhytomyr, 10002, Ukraine
Investigational Site Number : 8040009

Odesa, 65025, Ukraine
MDH Research LLC Site Number : 8400006

Westerville, Ohio, 43081, United States
Neurology Associates, PA Site Number : 8400002

Maitland, Florida, 32761, United States
Neurology PC Site Number : 8400003

Knoxville, Tennessee, 37922, United States
North Central Neurology Associates, PC Site Number : 8400005

Cullman, Alabama, 35058, United States
UC Health, LLC Site Number : 8400008

Dayton, Ohio, 45417, United States
University of South Florida Site Number : 8400009

Tampa, Florida, 33612, United States
Velocity Clinical Research Site Number : 8400007

Savannah, Georgia, 31406, United States

Conditions

Explore the condition pages connected to this study.

RELAPSING MULTIPLE SCLEROSIS